Former Pfizer Worldwide Business Development Director Joins Australian Drug Development Company Agenix
05 June 2012 - 2:24PM
Business Wire
Australian-based drug and development company Agenix Limited
(ASX:AGX) today announced the appointment of Dr Paul Resnick as
business advisor. Dr Resnick will initially focus on the Company’s
revolutionary blood clot diagnostic ThromboView®.
Dr Resnick is the former Vice President of Business Development
at privately held US-based biotechnology business Intellikine Inc
where he played a key role in securing a $489 million program
licensing deal and the subsequent sale of the business in December
2011 to Japan’s Takeda Pharmaceutical Co for $310 million.
Before joining Intellikine, Dr Resnick was Senior Director of
Worldwide Business Development at Pfizer Inc (NYSE: PFE). He
previously held roles at Rinat Neuroscience, InterMune, Roche
Pharmaceuticals and practiced medicine. At Rinat Neuroscience, he
played a key role in its acquisition by Pfizer Inc.
Agenix Chairman and Chief Executive Officer Nicholas Weston
said, "Paul adds significant depth and experience to our team and
will provide strategic guidance and negotiation support as we
progress our promising commercial and clinical programs.”
“Agenix is continuously engaged with potential strategic
corporate partners in multiple geographies. Paul will help us
manage this important process in a timely and efficient manner to
achieve the best possible results that create shareholder
value.”
Dr Resnick said “I see significant unrecognized potential and
value in Agenix and the exciting assets it has developed. There is
a compelling proposition in ThromboView's strong clinical safety
and efficacy profile and its potential value in a range of clinical
applications.”
Follow Agenix on Twitter or LinkedIn.
ThromboView® is a registered trademark of Agen
Biomedical Limited, a wholly owned subsidiary of Agenix
Limited.
About Agenix
Agenix is a public, clinical-stage company focused on the
discovery and development of innovative monoclonal antibody blood
clot diagnostics, and small molecule drugs for the treatment of
hepatitis B and other serious diseases. Agenix’s most advanced
diagnostic candidate, ThromboView®, a novel radio-labelled
monoclonal antibody imaging agent, has completed two Phase 2
clinical trials, and is ideal to diagnose patients indicated for
suspected acute pulmonary embolism (PE), with a positive D-dimer
blood test or moderate to high pre-test probability of PE, as a
replacement diagnostic test for patients with suspected PE where
V/Q scans are a first line choice and are unlikely to deliver a
diagnostic result, as a confirmatory diagnostic where CT is used as
a first-line diagnostic test, the scan result is negative and the
clinical probability of disease is high or moderate and as a
replacement diagnostic where CTPA is an inappropriate choice based
on radiation exposure, renal impairment or contrast allergy. Agenix
is also developing AGX 1009, a next-generation reverse
transcriptase inhibitor (NtRTI) prodrug of tenofovir, for which a
CTA is planned to be filed with the Chinese FDA in the second half
of 2012 and for which the Company plans to advance into Phase 1 in
the second half of 2013. Agenix owns all the patent rights to both
ThromboView® and AGX 1009. In August 2010, Agenix entered into a
collaborative partnership with the Institute of Medicinal
Biotechnology of the Chinese Academy of Medical Sciences, part of
the Ministry of Health to purchase AGX 1009 and preclinical work is
being conducted in Beijing, China by the Institute of Pharmacology
and Toxicology of the Academy of Military Medical Sciences. Agenix
has taken successfully from laboratory to global commercialisation
then commercial exit more than 20 products over four technology
platforms since listing on the Australian Securities Exchange in
1987.
Agenix (ASX:AGX)
Historical Stock Chart
From May 2024 to Jun 2024
Agenix (ASX:AGX)
Historical Stock Chart
From Jun 2023 to Jun 2024
